(Q34982492)

5 August 2017

Serotonergic drugs in the treatment of depressive and anxiety disorders (English)

1 reference

5 August 2017

Johan A. Den Boer

1

1 reference

PubMed ID

12404310

5 August 2017

Fokko J. Bosker

series ordinal

2

1 reference

PubMed ID

12404310

5 August 2017

Bernhard R. Slaap

series ordinal

3

1 reference

5 August 2017

1 July 2000

1 reference

5 August 2017

Human Psychopharmacology

1 reference

5 August 2017

15

1 reference

5 August 2017

315-336

1 reference

5 August 2017

5

1 reference

Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis

5 August 2017

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

5-HT and antidepressants: new views from microdialysis studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Double-blind pilot trial of desipramine versus fluoxetine in panic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

The biochemistry of affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Efficacy of ondansetron in the treatment of generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Role of 5-HT in stress, anxiety, and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Augmentation with buspirone: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Obsessive-compulsive disorder and serotonin: is there a connection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

The 5-HT1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Sertraline in social phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Sertraline in the treatment of panic disorder: a double-blind multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A comparison of fluvoxamine and fluoxetine in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Serotonergic anxiolytics and treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Paroxetine efficacy in the treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Sertraline in social phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Benzodiazepines: anxiety-reducing activity by reduction of serotonin turnover in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Effects of trazodone on polysomnography, blood concentration and core body temperature in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Clinical Effects of the 5-HT1A Partial Agonists in Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Efficacy of fluvoxamine in severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Gepirone, a selective serotonin (5HT1A) partial agonist in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Controlled comparison of nefazodone and amitriptyline in major depressive inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Pindolol Induces a Rapid Improvement of Depressed Patients Treated With Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Ritanserin as adjunct to fluoxetine treatment of OCD patients with psychotic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Study and course of the psychological profile in 77 patients expressing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Sertraline in social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

5-HT and mechanisms of defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Assessment of the Efficacy of Buspirone in Patients Affected by Generalized Anxiety Disorder, Shifting to Buspirone From Prior Treatment with Lorazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Sertraline in the prevention of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Gepirone in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Sertraline for social phobia: a double-blind, placebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Maintenance Phase Efficacy of Sertraline for Chronic Depression A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Citalopram in the treatment of social phobia: a report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Paroxetine in social phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Sertraline in the treatment of patients with social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Clinical predictors of acute response with olanzapine in psychotic mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Diazepam alters brain 5-HT function in man: implications for the acute and chronic effects of benzodiazepines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Severity of depression and response to fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Nefazodone and imipramine in major depression: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Ondansetron in the treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Fluoxetine treatment of social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

The effect of citalopram in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1077%28200007%2915%3A5%3C315%3A%3AAID-HUP204%3E3.0.CO%3B2-Y

10.1002/1099-1077(200007)15:5<315::AID-HUP204>3.0.CO;2-Y

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12404310